MA51139A - Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer - Google Patents
Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancerInfo
- Publication number
- MA51139A MA51139A MA051139A MA51139A MA51139A MA 51139 A MA51139 A MA 51139A MA 051139 A MA051139 A MA 051139A MA 51139 A MA51139 A MA 51139A MA 51139 A MA51139 A MA 51139A
- Authority
- MA
- Morocco
- Prior art keywords
- piperidinocarbonylmethyl
- cancer
- treatment
- oxopiperazine derivatives
- oxopiperazine
- Prior art date
Links
- HJNZXOIKNJJSKO-UHFFFAOYSA-N 1-(2-oxo-2-piperidin-1-ylethyl)piperazin-2-one Chemical class C1CCCCN1C(=O)CN1CCNCC1=O HJNZXOIKNJJSKO-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599336P | 2017-12-15 | 2017-12-15 | |
| CH1522018 | 2018-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51139A true MA51139A (fr) | 2020-10-21 |
Family
ID=65003562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051139A MA51139A (fr) | 2017-12-15 | 2018-12-17 | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10710975B2 (fr) |
| EP (1) | EP3724178B1 (fr) |
| JP (1) | JP7307744B2 (fr) |
| KR (1) | KR20200101397A (fr) |
| CN (1) | CN111788191B (fr) |
| AU (1) | AU2018386327B2 (fr) |
| BR (1) | BR112020011925A2 (fr) |
| CA (1) | CA3085481A1 (fr) |
| IL (1) | IL275337B2 (fr) |
| MA (1) | MA51139A (fr) |
| MX (1) | MX2020006219A (fr) |
| RU (1) | RU2020123261A (fr) |
| SG (1) | SG11202005365WA (fr) |
| TW (1) | TWI810229B (fr) |
| WO (1) | WO2019118973A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL275337B2 (en) | 2017-12-15 | 2024-06-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopyrazine derivatives for cancer therapy |
| WO2020048827A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one |
| WO2020048828A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane |
| WO2020048826A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5 |
| WO2020048829A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de 3,9-diazaspiro[5.5]undécane |
| WO2020048830A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one |
| WO2020048831A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés 5-aryl-3,9-diazaspiro[5.5]undécan-2-one |
| WO2021144302A1 (fr) * | 2020-01-13 | 2021-07-22 | Inthera Bioscience AG | Biomarqueurs pour déterminer la sensibilité à des dérivés d'oxopipérazine et leurs méthodes d'utilisation |
| WO2021255239A1 (fr) * | 2020-06-19 | 2021-12-23 | Inthera Bioscience AG | Dérivés d'oxopipérazine pour le traitement du cancer |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| WO2024015229A1 (fr) * | 2022-07-15 | 2024-01-18 | Sutro Biopharma, Inc. | Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques |
| WO2024056732A1 (fr) * | 2022-09-16 | 2024-03-21 | Syngenta Crop Protection Ag | Composés amines cycliques à action pesticide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885995A (en) | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP2014291B1 (fr) | 2001-08-24 | 2011-10-26 | Yale University | Composés de pipérazinone en tant qu'agents anti-tumeur et anti-cancer |
| MXPA04003611A (es) | 2001-10-17 | 2004-07-30 | Schering Corp | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. |
| ES2345146T3 (es) * | 2002-11-18 | 2010-09-16 | Schering Corporation | Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| US20060094726A1 (en) | 2003-01-30 | 2006-05-04 | Jeffrey Kerns | Quinoline derivatives as nk-2 and nk-3 receptor antagonists |
| GB0314733D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| EP1909797A4 (fr) * | 2005-08-02 | 2013-02-27 | Neurogen Corp | Dipipérazinyl cétones et analogues apparentés |
| CN101341123A (zh) * | 2005-12-21 | 2009-01-07 | 因塞特公司 | 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺 |
| EP2611791A4 (fr) | 2010-08-12 | 2014-02-12 | Univ New York | Oligooxopipérazines et procédés pour leur préparation et leur utilisation |
| CA2833009A1 (fr) * | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Inhibiteurs du recepteur du facteur de croissance 1 analogue a l'insuline |
| AU2013202973C9 (en) | 2012-01-25 | 2016-12-22 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US9255086B2 (en) | 2012-02-16 | 2016-02-09 | New York University | Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics |
| JP2016510327A (ja) | 2013-01-19 | 2016-04-07 | ニューヨーク・ユニバーシティ | ｐ５３再活性化のためのオリゴオキソピペラジン |
| US11180481B2 (en) | 2014-04-15 | 2021-11-23 | New York University | Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction |
| AU2015264201A1 (en) * | 2014-05-21 | 2017-01-12 | New York University | Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression |
| IL275337B2 (en) | 2017-12-15 | 2024-06-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopyrazine derivatives for cancer therapy |
-
2018
- 2018-12-17 IL IL275337A patent/IL275337B2/en unknown
- 2018-12-17 RU RU2020123261A patent/RU2020123261A/ru unknown
- 2018-12-17 CN CN201880089454.7A patent/CN111788191B/zh active Active
- 2018-12-17 WO PCT/US2018/066027 patent/WO2019118973A1/fr unknown
- 2018-12-17 MA MA051139A patent/MA51139A/fr unknown
- 2018-12-17 CA CA3085481A patent/CA3085481A1/fr active Pending
- 2018-12-17 SG SG11202005365WA patent/SG11202005365WA/en unknown
- 2018-12-17 US US16/222,479 patent/US10710975B2/en active Active
- 2018-12-17 EP EP18830663.3A patent/EP3724178B1/fr active Active
- 2018-12-17 JP JP2020552682A patent/JP7307744B2/ja active Active
- 2018-12-17 KR KR1020207020485A patent/KR20200101397A/ko not_active Application Discontinuation
- 2018-12-17 MX MX2020006219A patent/MX2020006219A/es unknown
- 2018-12-17 BR BR112020011925-3A patent/BR112020011925A2/pt unknown
- 2018-12-17 AU AU2018386327A patent/AU2018386327B2/en active Active
- 2018-12-17 TW TW107145504A patent/TWI810229B/zh active
-
2020
- 2020-06-03 US US16/891,417 patent/US11306068B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201930286A (zh) | 2019-08-01 |
| CA3085481A1 (fr) | 2019-06-20 |
| RU2020123261A3 (fr) | 2022-02-16 |
| CN111788191B (zh) | 2024-06-04 |
| AU2018386327B2 (en) | 2023-04-13 |
| MX2020006219A (es) | 2020-12-03 |
| CN111788191A (zh) | 2020-10-16 |
| US20190185449A1 (en) | 2019-06-20 |
| AU2018386327A1 (en) | 2020-06-25 |
| IL275337B2 (en) | 2024-06-01 |
| SG11202005365WA (en) | 2020-07-29 |
| TWI810229B (zh) | 2023-08-01 |
| RU2020123261A (ru) | 2022-01-17 |
| WO2019118973A1 (fr) | 2019-06-20 |
| US20220213057A1 (en) | 2022-07-07 |
| EP3724178B1 (fr) | 2024-05-01 |
| JP2021506973A (ja) | 2021-02-22 |
| BR112020011925A2 (pt) | 2020-11-24 |
| US20200308139A1 (en) | 2020-10-01 |
| IL275337A (en) | 2020-07-30 |
| US10710975B2 (en) | 2020-07-14 |
| KR20200101397A (ko) | 2020-08-27 |
| US11306068B2 (en) | 2022-04-19 |
| IL275337B1 (en) | 2024-02-01 |
| EP3724178A1 (fr) | 2020-10-21 |
| JP7307744B2 (ja) | 2023-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA47121A (fr) | Molécules de liaison pour le traitement du cancer | |
| MA43283A (fr) | Procédés et compositions pour le traitement du cancer | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA41123A (fr) | Polythérapie pour le traitement du cancer | |
| MA47408A (fr) | Traitement du cancer | |
| MA47776A (fr) | Polythérapies pour le traitement du cancer du sein | |
| MA50943A (fr) | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein | |
| MA52627A (fr) | Traitement du cancer | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |